United States · Platforms & data · Yahoo Finance

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Published by Yahoo Finance · United States 8 h ago

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMOSOUTH SAN FRANCISCO, Calif., Oct. 23, 2026…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

MarketBeat

2,406 International Business Machines Corporation $IBM Shares Sold by Culbertson A N & Co. Inc.

The Motley Fool

The Federal Reserve's Latest October Inflation Forecast Has Arrived, and It's Terrible News for Wall Street

Seeking Alpha

Eurozone flash composite PMI falls to 51.9 in October; services, and manufacturing expansion slows

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Kemira Q3 2026 slides: revenue rises but margins hit by cost inflation

Stocktwits